πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 429 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12414963

Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resist

Northwestern University Β· Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12410209

Modified glucocorticoids

The Board of Regents of the University of Texas System Β· Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12402611

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12385044

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12385043

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12378553

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12378280

Deoxynucleic guanidines (DNG)-modified oligonucleotides and methods of synthesizing deoxyn

Northwestern University Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331334

Modified urokinase-type plasminogen activator polypeptides and methods of use

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12331307

Modified immunization vectors

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12317874

Method of using a genetically modified mouse that expresses human albumin

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12318418

Modified adenoviruses

University College Cardiff Consultants Limited Β· Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290573

Modified RNAi agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12268688

Compositions and methods of use for modified release minoxidil

Veradermics Incorporated Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12269801

Modified amino acids

Sutro Biopharma, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12250931

Genetically modified mouse with a humanized PNPLA3 gene and methods of use

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252552

Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates

Sutro Biopharma, Inc. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226403

Tebipenem pivoxil immediate and modified release oral dosage forms

SPERO THERAPEUTICS, INC. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221622

Modified pluripotent cells

The Regents of the University of California Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215162

BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12203072

Chemically modified single-stranded rna-editing oligonucleotides

ProQR Therapeutics II B.V. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173062

Modified TNF-Ξ± antibodies and uses thereof

Bright Peak Therapeutics AG Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173337

Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and m

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168767

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161674

CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted